Not yet recruiting
Prospective, multicenter, randomized study on combined LT4 + LT3 therapy versus LT4 in the control of TSH in patients with advanced thyroid cancer treated with tyrosine kinase inhibitors.
2026-526113-28-00· Phase 4· Ceinge Biotecnologie Avanzate Franco Salvatore S.c.a.r.l.· Source
Not yet recruiting
A Multicentre, open label, Phase I-Ib Clinical Trial Combining Melanoma-Specific Peptide Vaccination (UniCanVax) and Anti PD-1 Inhibitor (Nivolumab) in Immune Checkpoint Blockade Refractory Metastatic or Unresectable Stage III/IV Melanoma Patients
2025-524486-25-00· Phase 1· Humanitas Mirasole S.p.A.· Source
Recruiting
A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF
NCT07761117· Phase 3· AstraZeneca· Source
Recruiting
A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer
NCT07673887· Phase 3· Astellas Pharma Global Development, Inc.· Source
Recruiting
A phase 2, multicentric study to assess the efficacy and safety of maribavir treatment in hematopoietic stem cell transplant (HSCT) recipients with cytomegalovirus (CMV) infection with a medical condition that contraindicate the administration of ganciclovir, valganciclovir or foscarnet and in those who discontinued first line preemptive therapy with ganciclovir, valganciclovir or foscarnet due to toxicity or intolerance.
2025-521074-34-00· Phase 2· Gruppo Italiano Per Il Trapianto Di Midollo Osseo Cellule Staminali Emopoietiche E Terapia Cellulare· Source
Recruiting
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
NCT07567001· Phase 3· Novo Nordisk A/S· Source
Recruiting
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
NCT07513376· Phase 3· Merck Sharp & Dohme LLC· Source
Recruiting
A Trial of Tarlatamab in Patients With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) and ECOG PS 2
NCT07203053· Phase 2· ETOP IBCSG Partners Foundation· Source
Recruiting
A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)
NCT07489495· Phase 3· Merck Sharp & Dohme LLC· Source
Recruiting
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
NCT07351058· Phase 3· Hoffmann-La Roche· Source
Recruiting
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
NCT07351045· Phase 3· Hoffmann-La Roche· Source
Active, not recruiting
A trial to learn how well AZD0292 works, how safe it is, and how it moves throughout the body over time in people with bronchiectasis and chronic PsA colonization
2025-523009-14-00· Phase 2· AstraZeneca AB· Source
Recruiting
Phase II trial of amivantamab plus monochemotherapy in platinum unfit NSCLC patients with EGFR exon20 insertion mutations
2025-520676-26-00· Phase 2· Fondazione Ricerca Traslazionale· Source
Recruiting
Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation
NCT07211958· Phase 3· Syndax Pharmaceuticals· Source
Recruiting
Observational, Prospective, Multi-centric Study Exploring HER2 Mutations Incidence and Therapeutic Management in aNSCLC
NCT07356544· Gruppo Oncologico Italiano di Ricerca Clinica· Source
Contact: Marcello Tiseo, MD, PhD
Recruiting
Randomized phase II trial of Cemiplimab plus OSE2101 (TEDOPI®) as maintenance therapy in ctDNA positive NSCLC.
2024-519262-42-00· Phase 2· Fondazione Ricerca Traslazionale· Source
Recruiting
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
NCT06340568· Phase 3· BioNTech SE· Source
Recruiting
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
NCT06881784· Phase 3· Revolution Medicines, Inc.· Source
Recruiting
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
NCT06921785· Phase 3· AstraZeneca· Source
Recruiting
A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
NCT06846671· Phase 3· BeOne Medicines· Source
Recruiting
Trial on the Biological and Clinical Effects of Acetyl-L-carnitine in ALS
NCT06126315· Phase 2/3· Mario Negri Institute for Pharmacological Research· Source
Recruiting
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
NCT06855498· Phase 3· Incyte Corporation· Source
Recruiting
Phase II single arm study with CABozantinib in Non-Small Cell Lung Cancer patients with MET
deregulation
NCT03911193· Phase 2· Fondazione Ricerca Traslazionale· Source
Recruiting
Regorafenib for Recurrent Meningioma (MIRAGE Trial)
NCT06275919· Phase 2· Istituto Oncologico Veneto IRCCS· Source
Recruiting
A Study to Evaluate the Combination of Platinum-pemetrexed Based Chemotherapy Plus Lorlatinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) With Exclusively Extracranial Disease Progression on Lorlatinib
NCT06378892· Phase 2· Centro di Riferimento Oncologico - Aviano· Source
Contact: Metro Giulio
Recruiting
Comparison of Allegra vs Sapien Transcatheter Aortic Valves in Valve-In-Valve Indication
NCT06049654· Fundación EPIC· Source
Contact: RAÚL MORENO GÓMEZ, MD, PhD
Recruiting
A Phase 1/2 study of Enzomenib (DSP-5336) in Patients with Acute leukemia
2022-502741-10-00· Phase 1/2· Sumitomo Pharma America Inc.· Source
Active, not recruiting
Resumption of Anticoagulation After Major Gastrointestinal Bleeding in Patients With Atrial Fibrillation
NCT07901699· Società Italiana di Medicina Interna· Source
Recruiting
A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
NCT06091865· Phase 3· Regeneron Pharmaceuticals· Source
Contact: Clinical Trials Administrator
Active, not recruiting
Toward Molecular Profiling of Parkinson's Disease in Easily Accessible Biological Matrices
NCT07480187· Azienda Ospedaliera di Perugia· Source
Recruiting
National Database on Primary Sclerosing Cholangitis (PSC)
NCT05618145· University of Milano Bicocca· Source
Contact: Olivia Morelli
Recruiting
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
NCT05533697· Phase 1/2· ModernaTX, Inc.· Source
Recruiting
The Italian Transthyretin Amyloidosis Web-Network
NCT05444920· Fondazione IRCCS Policlinico San Matteo di Pavia· Source
Contact: Cinzia Zuchi, MD
Active, not recruiting
Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED)
NCT04884282· Phase 2· Fondazione Ricerca Traslazionale· Source
Not yet recruiting
Phase II, open label, single arm, multicenter study to assess the activity and safety of ALectinib as NE O adjuvant therapy in patients with anaplastic lymphoma kinase positive (ALK+) locally advanced Stage III Non Small Cell Lung Cancer (NSCLC): ALNEO trial-GOIRC-01-2020
2024-519106-12-00· Phase 2· G.O.I.R.C. Gruppo Oncologico Italiano Di Ricerca Clinica· Source
Recruiting
AutoInflammatory Disease Alliance Registry (AIDA)
NCT05200715· University of Siena· Source
Contact: Elena Bartoloni Bocci
Recruiting
Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients
NCT03567889· Phase 3· Philogen S.p.A.· Source